Literature DB >> 2125370

D-dimer in local thrombolytic therapy with low doses of recombinant human tissue-type plasminogen activator (rt-PA) in patients with peripheral arterial occlusive disease.

R Koppensteiner1, W Speiser, E Minar, R Ahmadi, H Ehringer.   

Abstract

The generation of D-dimer was studied in the course of local thrombolytic therapy of peripheral arterial occlusions with low doses of recombinant human tissue-type plasminogen activator (rt-PA) in 7 patients. Intermittent local application of rt-PA resulted in a marked increase in D-dimer exceeding values usually seen after intravenous application of manifold higher doses used in myocardial infarction. The increase in D-dimer was related to the estimated thrombus size (length of the occlusion) and the total dose of rt-PA applied. During local rt-PA infusion of 6 of 7 patients maintained plasminogen activator inhibitor capacity (PAI-cap) between 34% and 79% of their corresponding pre-treatment levels; detectable levels of PAI-cap in circulating blood during the procedure did not interfere with the success of therapy.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2125370

Source DB:  PubMed          Journal:  Thromb Haemost        ISSN: 0340-6245            Impact factor:   5.249


  1 in total

1.  Effect of Crizanlizumab, a P-Selectin Inhibitor, in COVID-19: A Placebo-Controlled, Randomized Trial.

Authors:  Thorsten M Leucker; William O Osburn; Paula Reventun; Kimberley Smith; Brian Claggett; Bridget-Anne Kirwan; Sophie de Brouwer; Marlene S Williams; Gary Gerstenblith; David N Hager; Michael B Streiff; Scott D Solomon; Charles J Lowenstein
Journal:  JACC Basic Transl Sci       Date:  2021-12-08
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.